

## **Invitation to Presentation of Promore Pharma's Interim report for the second quarter 2018**

***STOCKHOLM, 14 August, 2018 –Promore Pharma AB (publ) publishes its interim report for the second quarter 2018 at 16.00 CET on 20 August 2018.***

The day after, 21 August, the company will host a webcast telephone conference at 09.00 CET, with President and CEO Jonas Ekblom and CFO Jenni Björnulfson. After the presentation there will be a Q&A session. The presentation will be held in English. The conference can be accessed via computer, tablet or telephone.

To join the web conference, please use the following link:  
<https://global.gotomeeting.com/join/903872509>

To join the telephone conference, please use one of the following numbers:

Sweden: +46 853 527 836

Denmark: +45 43 31 47 82

Finland: +358 923 17 0568

Norway: +47 23 16 23 30

United Kingdom: +44 330 221 0088

USA: +1 (646) 749-3129

Use the access code 903-872-509 to join the meeting.

The telephone conference and the presentation material will be available on the company's website after the call; [www.promorepharma.com](http://www.promorepharma.com).

### **For additional information, please contact**

Jonas Ekblom, VD

Tel: [+46] 736 777 540

E-mail: [jonas.ekblom@promorepharma.com](mailto:jonas.ekblom@promorepharma.com)

Jenni Björnulfson, CFO

Tel: [+46] 708 55 38 05

E-mail: [jenni.bjornulfson@promorepharma.com](mailto:jenni.bjornulfson@promorepharma.com)

### **Promore Pharma in brief:**

Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides for the bioactive wound care market. The company's aim is to develop two first-in-category products for indications where very few efficacious prescription pharmaceuticals are available, thus, addressing high unmet medical needs. Promore Pharma's two projects, PXL01 and LL-37, are in late stage clinical phase. PXL01, that will be used for prevention of post-surgical adhesions and scars, is being prepared for clinical Phase III-studies in patients undergoing tendon repair surgery in the hand. LL-37 is being prepared for a clinical Phase IIb study in patients with venous leg ulcers. The product candidates can also be deployed for other indications, such as preventing dermal scarring and treatment of diabetic foot ulcers. The company is listed on Nasdaq First North with Redeye AB as Certified Adviser.